Module 5: Additional Resources

COVID-19 Vaccination after mAb Administration

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the US 

• Non-hospitalized COVID-19 patients who previously received passive antibody therapy
  
• There is no longer any need to delay vaccination following receipt of monoclonal antibody or convalescent plasma beyond recovery from the acute illness (if symptoms were present) and criteria to discontinue isolation have been met. 
  
• Hospitalized COVID-19 patients 
  
• Follow guidelines from CDC Advisory Committee on Immunization Practices 

Reporting Cadence

Sites with inventory of USG-purchased COVID-19 therapeutics must provide information on product utilization, wastage and stock on hand

COVID-19 Therapeutic Resources

• Administration for Strategic Preparedness and Response
  
• For the latest information on all COVID-19 therapeutics, refer to:
  
• FDA’s COVID-19 EUA Information
  
• ASPR’s COVID-19 Therapeutics Resources
  
• Still have questions? Reach out to HHS COVID 19 Therapeutics Email covid19therapeutics@hhs.gov